Cullinan Therapeutics, Inc. (CGEM)
9.21
+0.14
(+1.54%)
USD |
NASDAQ |
Nov 20, 10:46
Cullinan Therapeutics Cash from Operations (Quarterly) : -43.08M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -43.08M |
| June 30, 2026 | -38.22M |
| March 31, 2026 | -46.04M |
| December 31, 2025 | -38.11M |
| September 30, 2025 | -36.88M |
| June 30, 2025 | -57.61M |
| March 31, 2025 | -43.16M |
| December 31, 2024 | -36.63M |
| September 30, 2024 | -34.14M |
| June 30, 2024 | -36.29M |
| March 31, 2024 | -38.25M |
| December 31, 2023 | -18.13M |
| September 30, 2023 | -34.14M |
| June 30, 2023 | -31.01M |
| Date | Value |
|---|---|
| March 31, 2023 | -51.00M |
| December 31, 2022 | -24.98M |
| September 30, 2022 | -54.35M |
| June 30, 2022 | -25.42M |
| March 31, 2022 | -21.91M |
| December 31, 2021 | -15.17M |
| September 30, 2021 | -10.55M |
| June 30, 2021 | -16.20M |
| March 31, 2021 | -1.515M |
| December 31, 2020 | -9.436M |
| September 30, 2020 | -9.071M |
| June 30, 2020 | -6.25M |
| March 31, 2020 | -5.015M |
| December 31, 2019 | -4.869M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Climb Bio, Inc. | -12.00M |
| Oncolytics Biotech, Inc. | -6.754M |
| Sangamo Therapeutics, Inc. | -19.28M |
| Sarepta Therapeutics, Inc. | 59.97M |
| Anixa Biosciences, Inc. | -1.77M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 51.64M |
| Cash from Financing (Quarterly) | 1.062M |
| Free Cash Flow | -165.47M |
| Free Cash Flow Per Share (Quarterly) | -0.6669 |
| Free Cash Flow to Equity (Quarterly) | -43.02M |
| Free Cash Flow to Firm (Quarterly) | -43.08M |
| Free Cash Flow Yield | -27.61% |